{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Day 3 post-administration of AP1903."},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Day 7 post-administration of AP1903."},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Day 14 post-administration of AP1903."},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Day 28 post-administration of AP1903."},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Day 56 post-administration of AP1903."}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"To assess the incidence of GvHD treatment failure, defined as no response, progression, administration of additional therapy for GvHD, or mortality post-administration of AP1903.","groups":[{"description":"Patients who did not move forward to DLI","id":"OG000","title":"Transplant Only"},{"description":"Proceeded to DLI per protocol","id":"OG001","title":"Transplat Plus DLI"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patient who received AP1903","reportingStatus":"POSTED","timeFrame":"Day 3, 7, 14, 28, and 56 post-administration of AP1903.","title":"To Assess the Incidence of GvHD Treatment Failure Post-administration of AP1903.","type":"SECONDARY","unitOfMeasure":"Participants"}